CE-Ventures, the corporate venture capital platform of Crescent Enterprises, has invested $38 million in Freya Biosciences in a Series A funding round. Freya Biosciences is a biotech company specializing in women’s health, particularly in microbial immunotherapies for reproductive health conditions. This funding will support the development of Freya’s lead drug candidate, an investigational vaginal microbial immunotherapeutic targeting infertility in women. The funding will also drive the evolution of Freya’s data science platform, focusing on deep microbiome sequencing and immune biomarker profiling. The investment is part of CE-Ventures’ commitment to exploring innovative fields and its belief in the potential of microbial immunotherapies. Other investors in the funding round include Sofinnova Partners, OMX Ventures, and Angelini Ventures.
$38 Million Funding Boost for Breakthroughs: Freya Biosciences Secures CE-Ventures’ Support
Latest from Blog
VCFA Group Closes $1225M Venture Partners VII Fund
TLDR: VCFA Group closed VCFA Venture Partners VII fund with $122.5 million in commitments Transition marks continuation of VCFA’s pioneering legacy in the secondary private equity space VCFA Group, a pioneer in
VCFA Group’s Venture Partners VII Fund Raises $1225 Million
TLDR: VCFA Group closed its latest fund, VCFA Venture Partners VII, with $122.5 million in commitments. The fund focuses on smaller and more complex purchases of later-stage venture capital and growth equity
Revolutionizing Payments: $20M Raised for Stablecoin Network Development
TLDR: 1Money has raised over $20 million in seed funding to develop a stablecoin payments network. The network aims to offer instant transaction confirmation, low-cost fees, multicurrency support, compliance mechanisms, and scalability.
Top AI Trends and Startups Shaping 2025 and Beyond
“`html TLDR: Israel is excelling in applicative and vertical AI, focusing on practical solutions in cybersecurity, healthcare, and defense rather than competing with tech giants in foundational AI models. Five key AI
Sand Hill Road: Steve Vassallo’s Early Investment Edge at Foundation Capital
“`html TLDR: Steve Vassallo, a general partner at Foundation Capital, focuses on early-stage investments, often being the first institutional investor for startups. He emphasizes the importance of owning a significant stake in